Healthcare / BiotechnologyNasdaqCM
$5.27
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-17.4M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$65M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-894.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-22.4M · FCF $-17.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-22.4M | $-22.4M | $-16.6M | $-23.5M | $-17.7M | $-20.7M | $-7.2M |
| EPS | -4.44 | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 | — |
| Cash Flow | |||||||
| Free Cash Flow | $-17.4M | $-17.4M | $-18.7M | $-15.3M | $-16.0M | $-11.2M | $-7.2M |
| Returns | |||||||
| ROE | -894.8% | -894.8% | -222.1% | 342.6% | -455.3% | -99.4% | -555.8% |
| Growth & Yield | |||||||
| EPS Growth | 59.1% | 59.1% | 96.5% | -963.0% | -952.0% | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.